The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1085-1097

  Gunn, Ellen J ^a   Williams, John T ^a   Huynh, Daniel T ^b   Iannotti, Michael J ^a   Han, Changho ^b   Barrios, Francis J ^c   Kendall, Stephen ^d   Glackin, Carlotta A ^d   Colby, David A ^b,c   Kirshner, Julia ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

chemotherapeutic approaches; drug resistance; microenvironment; Myeloma

Indexed keywords

ANDROGRAPHOLIDE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; PARTHENOLIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL VIABILITY; CYTOTOXICITY; HUMAN; HUMAN CELL; LC 50; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; STEM CELL; STRUCTURE ACTIVITY RELATION;

ANDROGRAPHIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; NF-KAPPA B; PLANT EXTRACTS; SESQUITERPENES; TANACETUM PARTHENIUM;

EID: 79957443436     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.555891     Document Type: Article

References (50)

1. Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1997;11:349-361. (Pubitemid 27193730)
2. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
3. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77:2688-2693.
4. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-877. (Pubitemid 41060226)
5. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and selfrenewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056-1065. (Pubitemid 30062731)
6. Pilarski LM, Seeberger K, Coupland RW, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002;30:221-228. (Pubitemid 34203728)
7. Reiman T, Seeberger K, Taylor BJ, et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001;98:2791-2799.
8. Pilarski LM, Baigorri E, Mant MJ, et al. Multiple myeloma includes phenotypically defined subsets of clonotypic CD20 B cells that persist during treatment with rituximab. Clin Med Oncol 2008;2:275-287.
9. Kirshner J, Thulien KJ, Martin LD, et al. A unique threedimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008;112:2935-2945.
10. Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 1989;105:223-235. (Pubitemid 19053272)
11. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999;93:3044-3052. (Pubitemid 29200797)
12. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004;32:685-691. (Pubitemid 39092730)
13. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436. (Pubitemid 44050137)
14. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564-1573. (Pubitemid 44118771)
15. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163-4169. (Pubitemid 40720758)
16. Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep 1995;12:271-276.
17. Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-129. (Pubitemid 29138143)
18. Wiedhopf RM, Young M, Bianchi E, Cole JR. Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide. J Pharm Sci 1973;62:345.
19. Woynarowski JM, Konopa J. Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 1981;19:97-102. (Pubitemid 11104877)
20. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004;208:143-153. (Pubitemid 38624155)
21. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330-7344. (Pubitemid 39382136)
22. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NFkappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004;15:885-890. (Pubitemid 39004343)
23. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26. (Pubitemid 38088695)
24. Suvannasankha A, Crean CD, Shanmugam R, et al. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 2008;14:1814-1822. (Pubitemid 351469468)
25. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-4435. (Pubitemid 351377809)
26. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19:4346-4349.
27. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004; 22:299-305. (Pubitemid 39012569)
28. Nasim S, Crooks PA. Antileukemic activity of aminoparthenolide analogs. Bioorg Med Chem Lett 2008;18:3870-3873.
29. Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008;111:5654-5662.
30. Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 2006;20:1073-1079. (Pubitemid 43797300)
31. Schmidt TJ. Helenanolide-type sesquiterpene lactones-III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg Med Chem 1997;5(4) 107: 645-653. (Pubitemid 27199388)
32. Nanduri S, Nyavanandi VK, Thunuguntla SS, et al. Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents. Bioorg Med Chem Lett 2004;14:4711-4717. (Pubitemid 39490294)
33. Hidalgo MA, Romero A, Figueroa J, et al. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 2005;144: 680-686. (Pubitemid 40445616)
34. Zhang Z, Chan GK, Li J, Fong WF, Cheung HY. Molecular interaction between andrographolide and glutathione follows second order kinetics. Chem Pharm Bull (Tokyo) 2008;56: 1229-1233.
35. Xia YF, Ye BQ, Li YD, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004;173:4207-4217.
36. Puri A, Saxena R, Saxena RP, Saxena KC, Srivastava V, Tandon JS. Immunostimulant agents from Andrographis paniculata. J Nat Prod 1993;56:995-999. (Pubitemid 23222198)
37. Choudhury BR, Haque SJ, Poddar MK. In vivo and in vitro effects of kalmegh (Andrographis paniculata) extract and andrographolide on hepatic microsomal drug metabolizing enzymes. Planta Med 1987;53:135-140. (Pubitemid 17057061)
38. Matsuda T, Kuroyanagi M, Sugiyama S, Umehara K, Ueno A, Nishi K. Cell differentiation-inducing diterpenes from Andrographis paniculata Nees. Chem Pharm Bull (Tokyo) 1994;42:1216-1225. (Pubitemid 24216646)
39. Manikam SD, Stanslas J. Andrographolide inhibits growth of acute promyelocytic leukaemia cells by inducing retinoic acid receptor-independent cell differentiation and apoptosis. J Pharm Pharmacol 2009;61:69-78.
40. Han C, Barrios FJ, Riofski MV, Colby DA. Semisynthetic derivatives of sesquiterpene lactones by palladium-catalyzed arylation of the alpha-methylene-gamma-lactone substructure. J Org Chem 2009;74:7176-7179.
41. Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol 2004;41(Suppl. 4):1-5. (Pubitemid 38649812)
42. Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 2009;57:239-247.
43. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759-766. (Pubitemid 32752455)
44. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336. (Pubitemid 38326254)
45. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-197. (Pubitemid 351380120)
46. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-1188. (Pubitemid 34618857)
47. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.
48. Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 2001;20:43-50. (Pubitemid 34074677)
49. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-1182. (Pubitemid 36722250)
50. Perez LE, Parquet N, Shain K, et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008;180:1545-1555.